BioPharma Resources

Drug Trial Radar · NCT05232916

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,250

Planned (sponsor's estimate)

Start

Dec 16, 2022

Primary completion

Dec 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Greenwich LifeSciences, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects.

Conditions

  • Breast Cancer

Interventions

  • PlaceboBiological

    0.9% Normal Saline

  • GLSI-100Biological

    500 mcg/mL GP2 and 125 mcg/mL GM-CSF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Breast Cancer-free Survival (IBCFS)Time frame: Median 4 years of follow-up (interim analyses planned)

Locations

179 sites in 10 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Mobile, Alabama · Not yet recruiting

  • City of Hope - Cancer Center Phoenix

    Goodyear, Arizona · Recruiting

  • Tucson Medical Center HealthCare

    Tucson, Arizona · Recruiting

  • City of Hope - Duarte Cancer Center

    Duarte, California · Recruiting

  • Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center

    Fullerton, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • University of California San Diego - Moores Cancer Center

    La Jolla, California · Recruiting

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • Stanford Medicine Cancer Center - Stanford Women's Cancer Center

    Palo Alto, California · Recruiting

  • University of California San Francisco - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • University of California Los Angeles - Hematology / Oncology Parkside

    Santa Monica, California · Recruiting

  • PIH Health Hospital - Whittier Hospital

    Whittier, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Yale Cancer Center - Smilow Cancer Hospital

    New Haven, Connecticut · Recruiting

  • Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope - Cancer Center Atlanta

    Newnan, Georgia · Recruiting

  • Northwestern University - Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • City of Hope - Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Maryland Oncology Hematology

    Annapolis, Maryland · Recruiting

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Minnesota Oncology

    Maple Grove, Minnesota · Recruiting

  • Siteman Cancer Center - Washington University Medical Campus

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Nebraska Medicine - University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada · Recruiting

  • Cooper University Health Care

    Camden, New Jersey · Active not recruiting

  • New York Oncology Hematology

    Albany, New York · Recruiting

  • New York-Presbyterian - Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Stony Brook University Cancer Center

    Stony Brook, New York · Recruiting

  • Oncology Hematology Care

    Cincinnati, Ohio · Recruiting

  • Hematology Oncology Associates

    Medford, Oregon · Not yet recruiting

  • Compass Oncology - Northwest Cancer Specialists

    Tigard, Oregon · Recruiting

  • Redeemer Health - Holy Redeemer Hospital

    Meadowbrook, Pennsylvania · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Cancer Specialists

    Knoxville, Tennessee · Not yet recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Not yet recruiting

  • Texas Oncology - Austin

    Austin, Texas · Recruiting

  • Texas Oncology - Dallas Presbyterian Hospital

    Dallas, Texas · Recruiting

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.